BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20972932)

  • 21. [Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy].
    Ketelsen D; Röthke M; Aschoff P; Merseburger AS; Lichy MP; Reimold M; Claussen CD; Schlemmer HP
    Rofo; 2008 Aug; 180(8):746-52. PubMed ID: 18512192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MR imaging and MR spectroscopy in prostate cancer management.
    Katz S; Rosen M
    Radiol Clin North Am; 2006 Sep; 44(5):723-34, viii. PubMed ID: 17030223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer.
    Eyal E; Bloch BN; Rofsky NM; Furman-Haran E; Genega EM; Lenkinski RE; Degani H
    Invest Radiol; 2010 Apr; 45(4):174-81. PubMed ID: 20177391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
    Lawrentschuk N; Fleshner N
    BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnosis of prostate capsular invasion by pelvic magnetic resonance imaging and serum level of prostate specific antigen].
    Mikata K; Uemura H; Fujinami K; Ohuchi H; Miyoshi Y; Ohta J; Osada Y; Jinza S; Kubota Y; Hosaka M; Nakatani I; Takebayashi S
    Hinyokika Kiyo; 2001 Jun; 47(6):385-8. PubMed ID: 11496393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
    Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
    Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
    Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
    Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
    Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Cattarino S; Lisi D; Gentilucci A; Alfarone A; Bernardo S; Passariello R; Gentile V
    Clin Cancer Res; 2010 Mar; 16(6):1875-83. PubMed ID: 20197480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic contrast enhanced MRI in prostate cancer.
    Alonzi R; Padhani AR; Allen C
    Eur J Radiol; 2007 Sep; 63(3):335-50. PubMed ID: 17689907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
    Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
    Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phased array magnetic resonance imaging for staging clinically localised prostrate cancer.
    Borre M; Lundorf E; Marcussen N; Langkilde NC; Wolf H
    Acta Oncol; 2005; 44(6):589-92. PubMed ID: 16294442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study.
    Perrotti M; Han KR; Epstein RE; Kennedy EC; Rabbani F; Badani K; Pantuck AJ; Weiss RE; Cummings KB
    J Urol; 1999 Oct; 162(4):1314-7. PubMed ID: 10492187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnostic work-up of the prostate carcinoma].
    Breul J; Paul R
    MMW Fortschr Med; 2006 Nov; 148(44):26-8, 30. PubMed ID: 17619436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.
    Hoeks CM; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Roobol MJ; Bul M; Hambrock T; Witjes JA; Fütterer JJ; Hulsbergen-van de Kaa CA; Barentsz JO
    Invest Radiol; 2014 Mar; 49(3):165-72. PubMed ID: 24220253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiparametric magnetic resonance imaging characterization of prostate lesions in the active surveillance population: incremental value of magnetic resonance imaging for prediction of disease reclassification.
    Bonekamp D; Bonekamp S; Mullins JK; Epstein JI; Carter HB; Macura KJ
    J Comput Assist Tomogr; 2013; 37(6):948-56. PubMed ID: 24270118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI of the prostate: clinical relevance and emerging applications.
    Mazaheri Y; Shukla-Dave A; Muellner A; Hricak H
    J Magn Reson Imaging; 2011 Feb; 33(2):258-74. PubMed ID: 21274967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnosis and treatment of early-stage prostate carcinoma. Improved prognosis--fewer complications].
    Bastian PJ; Stief CG
    MMW Fortschr Med; 2010 May; 152(19):36. PubMed ID: 20556999
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.